From creating the first cellular bone allograft to developing the first approved stem cell drug, remestemcel-L, we've focused our research and development on regenerative medicine.

In 1992, Osiris was founded with a singular mission: advance the area of cellular and regenerative medicine. We achieved this milestone in 2012 when we received approval for remestemcel-L in Canada and New Zealand for the treatment of graft-versus-host disease. There was no path to follow; no established research or related technologies on which to base our efforts. We defined the direction, creating a body of work and repository of intellectual property that not only validated our insights scientifically, but also defined the medical community’s understanding of this area of research.

Among our company’s innovations is the development of BioSmart™, an advanced proprietary process for tissue processing and cryopreservation that preserves and maintains the native properties and inherent functionality of the tissue. We have evolved from solely an R&D-focused biotech company into a more diverse organization focused on regenerative products for wound care, sports medicine, and orthopaedics. While we emphasize the manufacturing and marketing of viable, advanced products, we will also uphold our reputation for innovation, developing new, smarter approaches for healthcare.